Skip to content
Evigrade
CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Triazole derivatives, systemic antifungals

Updated · Methodology

Mechanism

Voriconazole is a strong CYP3A4 inhibitor and can raise the plasma concentrations of drugs that CYP3A4 metabolises (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Its SmPC lists cisapride among drugs that depend heavily on CYP3A4 for their metabolism. High plasma concentrations of these drugs are associated with serious or potentially life-threatening reactions (voriconazole SmPC, EMA). The pair has not been studied, but higher cisapride concentrations can prolong the corrected QT interval (QTc) and, rarely, cause torsade de pointes (voriconazole SmPC, EMA). Voriconazole itself has been associated with QTc prolongation (voriconazole SmPC, EMA).

Symptoms

The danger of the combination is prolongation of the corrected QT interval (QTc) and rare cases of torsade de pointes (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. Rare cases of arrhythmias (including torsade de pointes), cardiac arrest and sudden death have been reported in people taking voriconazole. These were usually seriously ill patients with several risk factors, such as previous cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicines that may have contributed (voriconazole label, US Food and Drug Administration, FDA).

Management

The combination is contraindicated. The voriconazole summaries of product characteristics (SmPCs) name cisapride among contraindicated drugs whose metabolism is highly dependent on CYP3A4, and the interaction table also marks the combination as contraindicated (voriconazole SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The US voriconazole label contraindicates drugs on the same basis, but cisapride is not on its list (voriconazole label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the voriconazole documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe voriconazole with it (voriconazole SmPC, EMA). No document states how long to wait after stopping voriconazole before starting cisapride. Monitor potassium, magnesium and calcium and correct them as needed before and during voriconazole treatment (voriconazole SmPC, EMA, and FDA label). Use voriconazole with caution in congenital or acquired QTc prolongation, cardiomyopathy (especially with heart failure), sinus bradycardia and symptomatic arrhythmias, and with other drugs known to prolong the QTc interval (voriconazole SmPC, EMA, and FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cisapride

Other interactions with Voriconazole